Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 15;15(14):3637.
doi: 10.3390/cancers15143637.

Management of Acute Promyelocytic Leukemia at Extremes of Age

Sabine Kayser  1   2 , Shannon E Conneely  3
Affiliations
Review

Management of Acute Promyelocytic Leukemia at Extremes of Age

Sabine Kayser et al. Cancers (Basel). .

Abstract

Tailored treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the outcome of acute promyelocytic leukemia (APL) from a uniformly fatal disease to one of the most curable malignant diseases in humans. Due to its high efficacy, ATO/ATRA is the standard first-line therapy in younger adult, non-high-risk APL patients. However, early death is still a major issue in APL, particularly in older patients. Thus, rapid diagnostics, immediate access to ATRA-based therapy, and supportive care are of utmost importance. Nevertheless, challenging situations occur, particularly in patients excluded from controlled studies with clinical knowledge mainly based on case reports and registries. Besides the treatment of newly diagnosed patients, managing toxicities and complications remains challenging. This review discusses the approach to the treatment of APL in elderly and pediatric patients.

Keywords: acute promyelocytic leukemia; elderly patients; pediatric patients; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. revised 4th ed. WHO Press; Geneva, Switzerland: 2017.
    1. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572. doi: 10.1182/blood.V72.2.567.567. - DOI - PubMed
    1. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., Shepherd L., Willman C., Bloomfield C.D., Rowe J.M., et al. All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 1997;337:1021–1028. doi: 10.1056/NEJM199710093371501. - DOI - PubMed
    1. Ablain J., de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011;117:5795–5802. - PubMed
    1. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 1990;76:1704–1709. doi: 10.1182/blood.V76.9.1704.1704. - DOI - PubMed

LinkOut - more resources